Figure 2From: Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration – evaluation in a clinical setting Change in mean visual acuity (LogMar) of reduced responders (black) and responders (white) at baseline (month 0) to the end of follow-up (month 6). Back to article page